Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.61 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.59 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.59 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
| ▸ | APP | P05067 | 4/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.51 |
| ▸ | AGXT | P21549 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12918621 | 1.00 | MAOB (0.62) | MAOBNPC1RAB9APARP10CASP3 | |
| SCHEMBL18635916 | 1.00 | MAOB (0.62) | MAOBNPC1RAB9APARP10CASP3 | |
| SCHEMBL1702909 | 1.00 | MAOB (0.62) | MAOBNPC1RAB9APARP10CASP3 | |
| SCHEMBL8929713 | 0.93 | MAOB (0.69) | MAOBNPC1RAB9APARP10CASP3 | |
| SCHEMBL891195 | 0.93 | MAOB (0.69) | MAOBNPC1RAB9APARP10CASP3 | |
| SCHEMBL762195 | 0.93 | MAOB (0.69) | MAOBNPC1RAB9APARP10CASP3 | |
| SCHEMBL8930213 | 0.93 | MAOB (0.69) | MAOBNPC1RAB9APARP10CASP3 | |
| SCHEMBL12885558 | 0.92 | MAOB (0.56) | MAOBNPC1RAB9APARP10CASP3 | |
| SCHEMBL14864480 | 0.92 | GSTP1 (0.63) | MAOBNPC1RAB9APARP10CASP3 | |
| SCHEMBL260484 | 0.91 | MAOB (0.58) | MAOBNPC1RAB9APARP10CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988692-B2 | Liquid crystal medium and liquid crystal device | MERCK PATENT GMBH (DE) | 2021-04-27 | — | — | US | disclosed |
| US-20200248077-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DEVICE | MERCK PATENT GMBH (DE) | 2020-08-06 | — | — | US | disclosed |
| US-10711196-B2 | Bimesogenic compounds and mesogenic media | MERCK PATENT GMBH (DE) | 2020-07-14 | — | — | US | disclosed |
| US-20200181492-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DEVICE | MERCK PATENT GMBH (DE) | 2020-06-11 | — | — | US | disclosed |
| US-10669484-B2 | Process of preparing a light modulation element | MERCK PATENT GMBH (DE) | 2020-06-02 | — | — | US | disclosed |
| US-10450508-B2 | Bimesogenic compounds and mesogenic media | MERCK PATENT GMBH (DE) | 2019-10-22 | — | — | US | disclosed |
| US-10392561-B2 | Bimesogenic compounds and mesogenic media | MERCK PATENT GMBH (DE) | 2019-08-27 | — | — | US | disclosed |
| US-10343982-B2 | Compounds and mesogenic media | MERCK PATENT GMBH (DE) | 2019-07-09 | — | — | US | disclosed |
| US-10190049-B2 | Mesogenic media and liquid crystal display | MERCK PATENT GMBH (DE) | 2019-01-29 | — | — | US | disclosed |
| US-20180187081-A1 | PROCESS OF PREPARING A LIGHT MODULATION ELEMENT | MERCK PATENT GMBH (DE) | 2018-07-05 | — | — | US | disclosed |
| US-20160222293-A1 | MESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2016-08-04 | — | — | US | disclosed |
| US-20150315470-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2015-11-05 | — | — | US | disclosed |
| US-20150210921-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2015-07-30 | — | — | US | disclosed |
| US-20150203756-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2015-07-23 | — | — | US | disclosed |
| US-20150203755-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2015-07-23 | — | — | US | disclosed |
| US-20150203755-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2015-07-23 | — | — | US | disclosed |
| US-20150175886-A1 | MESOGENIC MEDIA AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-20150175883-A1 | Bimesogenic Compounds and Mesogenic Media | MERCK PATENT GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-20150175883-A1 | Bimesogenic Compounds and Mesogenic Media | MERCK PATENT GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-20150090935-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2015-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450508-B2 | Bimesogenic compounds and mesogenic media | SP1, FOXM1, S100A11 | MAOB 3238/4885NPC1 2189/4885RAB9A 2884/4885 |
| US-20150210921-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | SP1, FOXM1, S100A11 | MAOB 3274/4885NPC1 2140/4885RAB9A 2745/4885 |
| US-20150175883-A1 | Bimesogenic Compounds and Mesogenic Media | SP1, FOXM1, S100A11 | MAOB 3274/4885NPC1 2140/4885RAB9A 2745/4885 |
| US-20150203756-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | SP1, FOXM1, S100A11 | MAOB 3274/4885NPC1 2140/4885RAB9A 2745/4885 |
| US-10343982-B2 | Compounds and mesogenic media | MTX1, NEFM, MTX2 | MAOB 535/4885NPC1 1714/4885RAB9A 836/4885 |
| US-20150315470-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | SP1, FOXM1, S100A11 | MAOB 3274/4885NPC1 2140/4885RAB9A 2745/4885 |
| US-20150203755-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | SP1, FOXM1, S100A11 | MAOB 3274/4885NPC1 2140/4885RAB9A 2745/4885 |
| US-10392561-B2 | Bimesogenic compounds and mesogenic media | SP1, FOXM1, S100A11 | MAOB 3274/4885NPC1 2140/4885RAB9A 2745/4885 |
| US-10711196-B2 | Bimesogenic compounds and mesogenic media | BMP2, NEFM, MTX1 | MAOB 578/4885NPC1 3539/4885RAB9A 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.